Showing 2831-2840 of 9766 results for "".
DermWireTV: Doximity Physician Compensation Report, EADV Updates, PsO in the Know
https://practicaldermatology.com/topics/psoriasis/dermwiretv-doximity-physician-compensation-report-eadv-updates-pso-in-the-know/19870/Doximity’s fourth annual Physician Compensation Report shows a widening of the gender pay gap. From biologics and investigational molecules for psoriasis to socks to prevent foot odors, the European Academy of Dermatology and Venereology annual meeting highlights emerging therapies for dermatology pCrisis Management: Office Operations, Part 1
https://practicaldermatology.com/topics/practice-management/crisis-management-office-operations-part-1/18181/How are primarily cosmetic dermatology practices dealing with shutdowns and preparing for the future? Host Neal Bhatia, MD discusses with Deirdre Hooper, MD, Ashish Bhatia, MD, Kevin Pinski, MD, and Nancy Samolitis, MD.The Emergence of Targeted Therapies for Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/the-emergence-of-targeted-therapies-for-prurigo-nodularis/48775/Christopher Bunick, MD, FAAD, discusses the importance of acknowledging prurigo nodularis as a distinct disease with its own molecular and transcriptomic features distinguishing it from atopic dermatitis, and how targeting the IL-31 receptor can change the game.Noah Worcester 2024: Dr. Hinshaw on Onychomycosis
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-hinshaw-onychomycosis/24587/Molly Hinshaw, MD, FAAD, summarizes her lecture on diagnosis and management of onychomycosis at the 2024 Noah Worcester Dermatological Society meeting.New Drug Developments in Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-drug-developments-in-dermatology/19971/Despite the COVID pandemic, the FDA had a nearly record year in drug approvals, says Vinod Nambudiri, MD, MBA, which has translated to new developments in dermatology. He discusses approvals of tirbanibulin 1% ointment for actinic keratoses and clascoterone cream 1% for acne, and how they fit into tDERM2020 Content Recap: Brad Glick, DO, MPH
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-content-recap-brad-glick-do/19840/DERM2020 Faculty Brad Glick, DO, MPH shares his thoughts on DERM2020 and some of the presentations around COVID.COVID-19 Impact: Interrupted EBD Regimens
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/covid-19-impact-on-interrupted-ebd-regimens/19764/Aesthetic treatments aren't considered essential at this time, but what do you do about patients who were in the middle of a series of energy-based treatments? Eric Bernstein, MD says the good news is that the skin doesn't forget. Now is a great time to focus on topical therapies that complement in-The Safety of New Systemics
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/the-safety-of-new-systemics/33159/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, provides an overview of the safey of systemic therapies such as JAK inhibitors and other similar drugs, giving dermatologists a high-level look at what they need to help clinical decision-making.Treatment Breaks for Super Responders: An Update from the GUIDE Study of Guselkumab in Psoriasis
https://practicaldermatology.com/topics/psoriasis/treatment-breaks-for-super-responders-an-update-from-the-guide-study-of-guselkumab-in-psoriasis/20222/Knut Schäkel, MD, a dermatologist at Heidelberg University Hospital in Germany, shares data on the withdrawal stage of the GUIDE study of guselkumab (Tremfya) in moderate-to-severe plaque psoriasis from his talk at the 2023 European Academy of Dermatology and Venereology meeting in Berlin.A Matter of Scales
https://practicaldermatology.com/series/diversity-and-equity-in-dermatology/a-matter-of-scales/19917/The "classic" descriptions of skin diseases and the scales used to assess disease severity often are based on white skin. But skin diseases can appear differently across skin types. The panelists discuss the need for updated tools, including the need to rethink skin type scales.